Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 8/20 | 0.45 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.43 |
| ▸ | KCNH1 | O95259 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 5/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10193834 | 0.94 | SCN2A (0.46) | BACE1BACE2SCN2ASCN10AKCNH1 | |
| SCHEMBL10193017 | 0.93 | BACE1 (0.47) | BACE1BACE2SCN2ASCN10AKCNH1 | |
| SCHEMBL10193243 | 0.92 | BACE1 (0.46) | BACE1BACE2SCN2ASCN10AKCNH1 | |
| SCHEMBL10193937 | 0.91 | BACE1 (0.45) | BACE1BACE2SCN2ASCN10AKCNH1 | |
| SCHEMBL10193843 | 0.91 | BACE1 (0.45) | BACE1BACE2SCN2ASCN10AKCNH1 | |
| SCHEMBL10192924 | 0.91 | RXFP1 (0.43) | BACE1BACE2SCN2ASCN10AKCNH1 | |
| SCHEMBL10193931 | 0.88 | BACE1 (0.46) | BACE1BACE2KCNH1KCNH2 | |
| SCHEMBL10193940 | 0.88 | AURKA (0.49) | BACE1BACE2KCNH1AURKARPS6KB1 | |
| SCHEMBL10193839 | 0.88 | BACE1 (0.45) | BACE1BACE2SCN2ASCN10AKCNH1 | |
| SCHEMBL10193271 | 0.87 | BACE1 (0.46) | BACE1SMN1; SMN2GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415756-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | Shionogi&Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120015961-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015961-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885SCN2A 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.